Vistagen's Social Anxiety Nasal Spray Trial Sends Stock Price Soaring
TL;DR Summary
San Francisco-based pharmaceutical company Vistagen experienced a surge in its stock price of over 1,000% after announcing positive results from a Phase III trial for its nasal spray in treating social anxiety disorder. The trial demonstrated statistically significant differences in subjective distress scores and clinician-assessed responders between the experimental drug and placebo.
- Vistagen's positive PhIII for social anxiety nasal spray pushes stock price up 1000+% Endpoints News
- Biotech Firm Vistagen Surges 1,370% on Social Anxiety Spray Trial Success Yahoo Finance
- Vistagen stock soars 1,272% on social anxiety spray data FierceBiotech
- Vistagen (NASDAQ:VTGN) Skyrockets over 600% on Positive Phase 3 Data for Social Anxiety Disorder - TipRanks.com TipRanks
- VistaGen Therapeutics (VTGN Stock) Exploded 3,471% Here’s Why Penny Stocks
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
64%
146 → 52 words
Want the full story? Read the original article
Read on Endpoints News